BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abraham JA, Golubnitschaja O. Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon? Per Med 2016;13:455-67. [PMID: 29767598 DOI: 10.2217/pme-2016-0013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Zhang X, Zhou S, Shi J, Xu Y, He J, Lin F, Wei A, Zhou L, Chen Z. Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion. J Cell Mol Med 2019;23:2399-409. [PMID: 30677226 DOI: 10.1111/jcmm.14055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Golubnitschaja O, Sridhar KC. Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. Clin Exp Metastasis 2016;33:743-55. [PMID: 27541751 DOI: 10.1007/s10585-016-9816-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
3 Song X, Wu A, Ding Z, Liang S, Zhang C. Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection. Cancer Res Treat 2020;52:789-97. [PMID: 32138467 DOI: 10.4143/crt.2019.749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wang W, Yan Y, Guo Z, Hou H, Garcia M, Tan X, Anto EO, Mahara G, Zheng Y, Li B, Kang T, Zhong Z, Wang Y, Guo X, Golubnitschaja O; Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine. All around suboptimal health - a joint position paper of the Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine. EPMA J 2021;:1-31. [PMID: 34539937 DOI: 10.1007/s13167-021-00253-2] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Golubnitschaja O, Yeghiazaryan K, Abraham JA, Schild HH, Costigliola V, Debald M, Kuhn W. Breast cancer risk assessment: a non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes. Amino Acids 2017;49:273-81. [PMID: 27812894 DOI: 10.1007/s00726-016-2357-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
6 Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, Krapfenbauer K, Mozaffari MS, Costigliola V. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J 2016;7:23. [PMID: 27800037 DOI: 10.1186/s13167-016-0072-4] [Cited by in Crossref: 178] [Cited by in F6Publishing: 162] [Article Influence: 29.7] [Reference Citation Analysis]
7 Torres Moral T, Sanchez-niubo A, Monistrol-mula A, Gerardi C, Banzi R, Garcia P, Demotes-mainard J, Haro J; the PERMIT Group. Methods for Stratification and Validation Cohorts: A Scoping Review. JPM 2022;12:688. [DOI: 10.3390/jpm12050688] [Reference Citation Analysis]
8 Abraham JA, Yeghiazaryan K, Golubnitschaja O. Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization. Per Med 2016;13:347-60. [PMID: 29749819 DOI: 10.2217/pme-2016-0014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]